Key Points:
- Anthropic PBC’s Nasdaq debut became the week’s defining IPO event, with the offering raising $81.34 billion and the stock finishing the week 7% above its IPO price.
- U.S. issuance remained selective as EIR Biopharma withdrew and Core Specialty Insurance entered the proposed IPO pipeline, while broader market weakness complicated the outlook for new listings.
- No significant traditional IPO activity was independently verified in Europe, Asia or Israel during the reporting period, underscoring the concentration of verified issuance developments in the United States.
Global IPO Markets Concentrate Around a Landmark U.S. Offering
Global IPO markets entered the November 16–20 trading period amid renewed volatility and concerns surrounding equity valuations and monetary-policy expectations. The United States generated the week’s most prominent verified primary-market event through Anthropic PBC’s public offering and subsequent Nasdaq debut. Although the transaction demonstrated the ability of a large technology issuer to attract substantial capital, broader equity-market pressure continued to influence investor risk appetite. Meanwhile, the available weekly data did not substantiate significant traditional IPO pricing activity across Europe, Asia or Israel. The resulting market picture reflects concentrated issuance rather than a broad expansion of listing activity across major financial centers.
United States — Anthropic’s Offering Demonstrates Scale Amid Market Pressure
Anthropic PBC (ANT) priced its offering at $83 per share and began trading on Nasdaq on November 19. The offering raised $81.34 billion, with the transaction reportedly priced above its marketed range of $70–$78. The stock subsequently recorded a 7% return from its IPO price through November 20, according to the supplied market data. The transaction represented the week’s most significant verified conventional IPO event. Elsewhere, Core Specialty Insurance (CORE) entered the proposed IPO pipeline with an estimated $250 million offering and JP Morgan identified as lead underwriter. EIR Biopharma, Inc. withdrew its IPO on November 16. These developments demonstrate that capital remains accessible for substantial issuers, although transaction execution and investor appetite continue to determine the pace of primary-market activity. The broader risk-off environment may also influence pricing expectations for companies preparing to enter the public markets.
Europe — Limited Verified Issuance Keeps the Pipeline Restrained
No significant traditional European IPO pricing, newly announced offering or withdrawal was independently verified for November 16–20. The absence of confirmed transactions leaves the week’s European primary-market activity comparatively subdued relative to the U.S. offering highlighted by Anthropic. While European companies may continue evaluating public-market financing opportunities, the available weekly data does not support identifying a significant transaction or a measurable change in regional IPO momentum. Monetary-policy conditions remain a broader consideration for the European issuance environment, particularly as borrowing costs, inflation expectations and institutional valuation requirements influence companies’ decisions regarding listing timing and pricing. Without verified offering data, the week’s regional activity should be characterized as limited rather than interpreted as evidence of a definitive market-wide contraction.
Asia — No Significant Traditional IPO Activity Verified
No significant new traditional IPO pricing or debut was independently verified across Hong Kong, Japan, mainland China, Singapore or India during November 16–20 in the sources reviewed. Similarly, no significant new IPO filings or regulatory approvals were independently verified for the reporting period. The available information therefore does not establish a weekly trend comparing Hong Kong listings with mainland China’s A-share IPO market. Asian primary markets remain important to the broader global issuance cycle, but the reporting period’s verified data does not support identifying a major transaction or quantifying regional capital raised. Institutional investors monitoring the region will need to evaluate subsequent filings, exchange announcements and confirmed pricing events before assessing whether listing momentum is strengthening or weakening.
Israel — No Significant New IPO Activity Identified
No significant new Israeli IPO pricing or primary listing was independently verified on the Tel Aviv Stock Exchange during November 16–20. The available weekly information did not identify a newly priced offering, a significant filing or a confirmed withdrawal that materially altered the domestic IPO pipeline. This limited activity contrasts with the major U.S. transaction recorded during the period and reinforces the uneven distribution of verified primary-market developments across regions. Israeli capital-market activity remains relevant to the global IPO assessment, but the reporting period does not provide sufficient verified transaction data to establish a meaningful change in domestic issuance momentum.
Next Session — Pipeline Developments and Market Stability Remain Central
Investors will continue monitoring Core Specialty Insurance’s proposed offering and the potential return of issuers seeking more favorable market conditions. Anthropic’s trading performance may also provide a reference point for investor demand toward large technology offerings. Volatility, monetary-policy expectations and valuation discipline remain central considerations for the next phase of global IPO activity. The broader pipeline will depend on whether market stability improves sufficiently to support additional transactions.